<DOC>
	<DOCNO>NCT02982590</DOCNO>
	<brief_summary>The purpose study compare novel oral anticoagulant apixaban standard therapy warfarin size reduction resolution leave ventricular thrombus 6 month .</brief_summary>
	<brief_title>Apixaban Versus Warfarin Patients With Left Ventricular Thrombus</brief_title>
	<detailed_description>Current treatment leave ventricular thrombus anti-coagulant blood thin agent know warfarin . Recently least three novel oral anticoagulant agent use treatment atrial fibrillation , pulmonary embolism deep vein thrombosis ( DVT ) . Novel oral anticoagulant drug require blood take INR monitoring , hence less visit convenience patient . Latest study also show less rate bleeding compare warfarin hence relatively safer .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Age 18 80 year old 2 . Presence LV thrombus spontaneous echo contrast ( SEC ) grade 3 4 ( Patel VG 1996 ) , regional wall motion abnormalities 3 . HASBLED score less 3 4 . No episodes major bleed past 6 month ) Major bleed define i. episode bleed significant drop haemoglobin ( Hb ) level least 2gm/dL Includes upper low gastrointestinal bleed ii . The need blood transfusion ( pack cell ) least 2 unit iii . Recent surgery bleeding complication lose Hb ( ) ( ii ) iv . Any intracranial bleeds neurological deficit 1 . Patient unstable arrhythmia and/or recurrent cardiogenic shock 2 . Patient large ischemic stroke recruitmentdefined involve &gt; 1/3 cerebral hemisphere deem high chance haemorrhagic transformation 3 . Patient permanent pacemaker 4 . Patient post valve replacement therapy 5 . Patient pregnant . 6 . Patient advance kidney disease stage V dialysis ( CrCl &lt; 15 mL/min ) 7 . Patient advance liver disease coagulopathy 8 . Patient organize old leave ventricular thrombus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>